Ocumension Therapeutics reported no changes to its share capital structure for the month ended 30 April 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing.

Authorized / Registered Capital • Authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001, translating to total authorized capital of USD 50,000.

Issued and Treasury Shares • Total issued shares stood unchanged at 836.33 million, comprising 815.38 million in circulation and 20.95 million held as treasury shares. • The company confirmed compliance with the Main Board’s minimum 25 % public-float requirement.

Equity Incentive Schemes • Employee Stock Option Plan (adopted 23 May 2018): 13.32 million options outstanding; no grants, exercises, cancellations or lapses occurred during the month. • 2021 Share Option Scheme: Outstanding options decreased slightly to 37.56 million after 35,495 options (0.04 million) lapsed; no new grants or exercises were recorded. • Total new shares issued from option exercises during the month: zero.

Share Award Scheme • Under the 2021 Share Award Scheme, 34,795 share awards lapsed, leaving 10.40 million shares covered by unvested awards. No new shares were issued and no treasury shares were transferred.

Other Securities • The company reported no activity involving warrants, convertibles or other share-issuance arrangements.

Overall, Ocumension ended April with an unchanged share count while modest lapses in option and award plans marginally reduced outstanding equity incentives.